Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (493 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: pfpatients withsafety andand efficacyin patients
  Phrases that lowered it: metformindiabetesand safetymalewith type
• Sponsor's past termination rate: 16.3% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 328 (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 67.4% (lowers risk) · Drug's FDA history
• Blinding: triple (raises risk) · Design
• Drug's FAERS reports with a death: 8.0% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor's past trials: 1072 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 5 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, metabolic: Yes (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 70 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes NCT01933672 · started 2013 · scored riskier than 9% of active trials completed
• Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes NCT01475461 · started 2011 · scored riskier than 33% of active trials completed
• A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin NCT02053103 · started 2014 · scored riskier than 58% of active trials terminated
• Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus NCT01336738 · started 2011 · scored riskier than 58% of active trials completed
• Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes NCT01338870 · started 2011 · scored riskier than 47% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.